Prediction of liver cancer treatment efficacy by CTC.

JRCT ID: jRCT1061230098

Registered date:07/02/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Cases of unresectable advanced hepatocellular carcinoma (HCC) for which treatment with immune checkp
• Date of first enrollment: 26/01/2024
• Target sample size: 20
• Study type: Observational

Outcome(s)

• Primary Outcome: Blood samples will be collected from patients with unresectable advanced hepatocellular carcinoma (HCC) before and after treatment with immune checkpoint inhibitors (regardless of treatment regimen or line), and circulating tumor cells (CTC) will be measured to verify the usefulness of CTC count in assessing treatment efficacy.
• Secondary Outcome: None

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

Select patients who meet all of the following criteria:
1) Diagnosed with hepatocellular carcinoma by imaging or histological examination.
2) Patients scheduled to receive treatment with immune checkpoint inhibitors.
3) Men and women aged 20 or older when obtaining consent.

Exclude criteria

Patients meeting any of the following criteria will not be included in this clinical study:
1) Patients with tumors originating from other organs.
2) Others deemed unsuitable as patients by the principal investigator for this study.

Related Information

• Primary Sponsor: Sugihara Takaaki
• Source(s) of Monetary Support: Tottori Prefecture